The latest price and purchasing channels of Risankizumab in 2025

Risankizumab/Risankizumab (Risankizumab), sold under the trade name Skyrizi, is a treatment for plaque psoriasis, psoriatic arthritis (PA), ulcerative colitis, and Crohn's disease (CD). The drug is a humanized monoclonal antibody that works primarily by targeting interleukin 23A (IL-23A) and is usually administered as a subcutaneous injection.

According to the latest information, Rishengizumab has been officially launched in the country. Due to its short time on the market, its domestic price and medical insurance situation are not yet clear. However, based on overseas markets, especially the European version of the original drug, each box of 150mg dose of subcutaneous injection is priced at more than 30,000 yuan, and the specific price will vary due to exchange rate fluctuations. This price is relatively expensive for patients.

It is worth noting that there are currently no generic drugs of Risenkizumab available at home or abroad, so patients must rely on the original drug when choosing this drug. In addition, since common side effects of Skyrizi include upper respiratory tract infections (such as nose and throat infections), patients need to pay close attention to their body's reaction during medication and communicate with their doctors in a timely manner.

In terms of purchasing channels, patients can purchase through hospital pharmacies, professional pharmacies and some compliant online drug platforms. When choosing purchase channels, patients are advised to give priority to medical institutions and drug retailers to ensure they obtain genuine and effective drugs. At the same time, understanding the drug usage guidelines and relevant medical insurance policies can also help patients reduce their financial burden.

In summary, risantekizumab provides a new treatment option for a variety of immune-mediated diseases, but its high price and limited purchase channels require patients to consider it carefully. Before using this drug, it is recommended to fully communicate with your doctor to understand all possible risks and benefits so that you can make an informed decision.

Reference materials:https://go.drugbank.com/drugs/DB14762